CN102438636A - 用于治疗心脏疾病的药物组合物 - Google Patents

用于治疗心脏疾病的药物组合物 Download PDF

Info

Publication number
CN102438636A
CN102438636A CN2010800211106A CN201080021110A CN102438636A CN 102438636 A CN102438636 A CN 102438636A CN 2010800211106 A CN2010800211106 A CN 2010800211106A CN 201080021110 A CN201080021110 A CN 201080021110A CN 102438636 A CN102438636 A CN 102438636A
Authority
CN
China
Prior art keywords
cells
pharmaceutical composition
cell
group
fgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800211106A
Other languages
English (en)
Chinese (zh)
Inventor
V·高森
R·戈登-贝瑞斯福特
C·霍姆西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celyad Oncology SA
Original Assignee
Cardio3 Biosciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardio3 Biosciences SA filed Critical Cardio3 Biosciences SA
Priority to CN201610828324.3A priority Critical patent/CN107028980A/zh
Publication of CN102438636A publication Critical patent/CN102438636A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1406—Septums, pierceable membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1412—Containers with closing means, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2010800211106A 2009-05-20 2010-05-20 用于治疗心脏疾病的药物组合物 Pending CN102438636A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610828324.3A CN107028980A (zh) 2009-05-20 2010-05-20 用于治疗心脏疾病的药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2009/056197 2009-05-20
EP2009056197 2009-05-20
PCT/EP2010/057004 WO2010133686A1 (en) 2009-05-20 2010-05-20 Parmaceutical composition for the treatment of heart diseases.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610828324.3A Division CN107028980A (zh) 2009-05-20 2010-05-20 用于治疗心脏疾病的药物组合物

Publications (1)

Publication Number Publication Date
CN102438636A true CN102438636A (zh) 2012-05-02

Family

ID=41323568

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800211106A Pending CN102438636A (zh) 2009-05-20 2010-05-20 用于治疗心脏疾病的药物组合物
CN201610828324.3A Pending CN107028980A (zh) 2009-05-20 2010-05-20 用于治疗心脏疾病的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610828324.3A Pending CN107028980A (zh) 2009-05-20 2010-05-20 用于治疗心脏疾病的药物组合物

Country Status (15)

Country Link
US (2) US9446076B2 (enExample)
JP (1) JP6029468B2 (enExample)
KR (1) KR101689415B1 (enExample)
CN (2) CN102438636A (enExample)
AU (1) AU2010251151B2 (enExample)
BR (1) BRPI1012116A2 (enExample)
CA (1) CA2762584A1 (enExample)
ES (1) ES2541212T3 (enExample)
IL (1) IL216399A0 (enExample)
MX (1) MX2011012183A (enExample)
NZ (2) NZ623454A (enExample)
RU (1) RU2595801C2 (enExample)
SG (1) SG175880A1 (enExample)
TW (1) TWI492707B (enExample)
WO (1) WO2010133686A1 (enExample)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103667440A (zh) * 2013-09-05 2014-03-26 谢小冬 Gata4基因snp位点的用途
CN104922155A (zh) * 2014-03-18 2015-09-23 中山大学孙逸仙纪念医院 治疗心脏疾病的细胞输送方法
CN105079791A (zh) * 2015-09-18 2015-11-25 郑榆坤 一种刺激体内内源干细胞的组合物及其应用
CN105324480A (zh) * 2013-06-28 2016-02-10 株式会社大塚制药工场 含有海藻糖及葡聚糖的哺乳动物细胞移植用溶液
CN106474456A (zh) * 2016-10-18 2017-03-08 广州赛莱拉干细胞科技股份有限公司 一种细胞制剂及其制备方法和应用
CN106619718A (zh) * 2016-10-18 2017-05-10 广州赛莱拉干细胞科技股份有限公司 一种细胞制剂及其制备方法和应用
CN107648592A (zh) * 2017-11-13 2018-02-02 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
CN108070645A (zh) * 2016-11-11 2018-05-25 中国科学院上海生命科学研究院 Stx-t在预防和/或治疗贫血或其相关疾病的应用
CN108472318A (zh) * 2015-06-30 2018-08-31 明尼苏达大学校董会 人源化心脏肌肉
CN109266604A (zh) * 2018-10-10 2019-01-25 浙江神雁精准医疗科技有限公司 包含干细胞活性物质的组合物及其制备方法
CN109769799A (zh) * 2019-03-20 2019-05-21 江苏瑞思坦生物科技有限公司 一种人脂肪组织保存液及其制备方法
WO2020030091A1 (zh) * 2018-08-10 2020-02-13 浙江楚沅生物科技有限公司 用于治疗组织坏死或改善心脏功能的药物
CN110945357A (zh) * 2017-07-18 2020-03-31 罗斯托克大学校行政管理中心1.1法律部 用于对心血管再生的响应的预测的方法
WO2020228705A1 (zh) * 2019-05-16 2020-11-19 龚笑海 一种心脏治疗和保护的药物组合物
US11673928B2 (en) 2015-03-03 2023-06-13 Regents Of The University Of Minnesota Genetically modified pig cells with an inactivated Etv2 gene
US12089574B2 (en) 2015-06-30 2024-09-17 Regents Of The University Of Minnesota Humanized skeletal muscle

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015127A2 (en) 2004-07-30 2006-02-09 Mayo Foundation For Medical Education And Research Treating cardiovascular tissue
US9765298B2 (en) 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
WO2009145761A1 (en) 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
WO2011057249A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
WO2013007284A1 (en) * 2011-07-08 2013-01-17 Mikael Sigvardsson A method for enriching mesenchymal stem cells and applications thereof
EP2833896A2 (en) * 2012-03-30 2015-02-11 University Of Southern California Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation
EP2841100A4 (en) * 2012-04-25 2016-03-23 Genera Istrazivanja D O O METHODS AND COMPOSITIONS FOR TREATMENT AND DIAGNOSIS OF MYOCARDIAL ACUTE INFARCTION
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
JP6687544B2 (ja) 2014-05-28 2020-04-22 チルドレンズ ホスピタル メディカル センター 前駆細胞を指向性分化によって胃組織に変換するための方法及びシステム
US10363278B2 (en) 2014-06-15 2019-07-30 Amnio Technology Llc Frozen therapeutic dose and package
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
CN107406830A (zh) 2014-12-30 2017-11-28 细胞治疗神经科学有限公司 Rpe细胞群和制备它们的方法
WO2017064688A1 (en) * 2015-10-15 2017-04-20 Cells For Cells, S.P.A. Neurite regeneration therapy based on exosomes derived from menstrual stem cells
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
SG11201903697WA (en) 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
NZ753873A (en) 2016-12-05 2023-01-27 Children’S Hospital Medical Center Colonic organoids and methods of making and using same
WO2018191673A1 (en) 2017-04-14 2018-10-18 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
CN109497038A (zh) * 2017-09-14 2019-03-22 青岛瑞思德生物科技有限公司 一种脂肪保存液及其制备方法
JP2020536529A (ja) 2017-10-10 2020-12-17 チルドレンズ ホスピタル メディカル センター 食道組織および／または臓器組成物およびそれを作製する方法
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
AU2018393494A1 (en) * 2017-12-29 2020-07-09 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
CN108244096B (zh) * 2018-01-10 2019-01-04 暨赛再生医学科技有限公司 一种长期保存过表达vegf的血管内皮祖细胞的保存液
CN108379662A (zh) * 2018-02-08 2018-08-10 深圳大图科创技术开发有限公司 一种干细胞在心脏移植模型的应用
CN108546757B (zh) * 2018-03-05 2021-09-07 上海长海医院 Zfpm2-as1在制备胃癌诊断试剂或试剂盒中的应用
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
AU2019339410A1 (en) 2018-09-12 2021-04-15 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
JP7610533B2 (ja) 2019-05-31 2025-01-08 チルドレンズ ホスピタル メディカル センター 造血幹細胞の生成および拡大方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015127A2 (en) * 2004-07-30 2006-02-09 Mayo Foundation For Medical Education And Research Treating cardiovascular tissue
US20080019944A1 (en) * 2006-07-24 2008-01-24 Mayo Foundation For Medical Education And Research Methods and Materials for Providing Cardiac Cells
WO2008109839A1 (en) * 2007-03-07 2008-09-12 Mayo Foundation For Medical Education And Research Cardiac-specific progenitor cells
EP2100954A1 (en) * 2008-03-10 2009-09-16 Assistance Publique - Hopitaux de Paris Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US20040071665A1 (en) 2000-09-05 2004-04-15 Yong-Fu Xiao Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US6921633B2 (en) * 2002-11-18 2005-07-26 Biolife Solutions Incorporated Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
KR100674783B1 (ko) * 2003-12-09 2007-01-25 (주)안트로젠 세포 이식을 위한 세포의 생산 방법
US9782439B2 (en) * 2005-01-27 2017-10-10 Japan Health Sciences Foundation Cell sheet containing mesenchymal stem cells
US20070059288A1 (en) * 2005-03-31 2007-03-15 Dinsmore Jonathan H Treatment for heart disease
WO2007033051A2 (en) * 2005-09-12 2007-03-22 Genzyme Corporation Thermally insulated transport container for cell-based products and related methods
EP2126052B1 (en) 2007-01-09 2014-12-10 Lead Pharma Cel Models IP B.V. Provision of new cardiomyocyte progenitor cells and cardiomyocytes derived therefrom
KR20080103637A (ko) * 2007-05-25 2008-11-28 주식회사 알앤엘바이오 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
FR2917381B1 (fr) 2007-06-15 2009-10-16 Ceva Sante Animale Sa Conditionnement plastique multicouche pour la conservation d'une composition pharmaceutique
KR101923152B1 (ko) * 2007-12-04 2018-11-28 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
EP2271209B1 (en) * 2008-03-27 2016-07-13 Biolife Solutions, Inc. Materials and methods for hypothermic collection of whole blood
WO2009145761A1 (en) 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
BE1018733A3 (fr) 2009-04-29 2011-07-05 Cardio3 Biosciences Sa Dispositif pour la delivrance d'un agent therapeutique.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015127A2 (en) * 2004-07-30 2006-02-09 Mayo Foundation For Medical Education And Research Treating cardiovascular tissue
US20080019944A1 (en) * 2006-07-24 2008-01-24 Mayo Foundation For Medical Education And Research Methods and Materials for Providing Cardiac Cells
WO2008109839A1 (en) * 2007-03-07 2008-09-12 Mayo Foundation For Medical Education And Research Cardiac-specific progenitor cells
EP2100954A1 (en) * 2008-03-10 2009-09-16 Assistance Publique - Hopitaux de Paris Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEHFAR,ET AL: "Cardiopoietic programming of embryonic stem cells for tumor-free heart repair", 《THE JOURNAL OF EXPERIMENTAL MEDICINE，ROCKEFELLER UNIVERSITY PRESS》, vol. 204, no. 2, 5 February 2007 (2007-02-05), pages 405 - 420, XP002462528, DOI: 10.1084/jem.20061916 *
J.M.BAUST,ET AL: "Modulation of the cryopreservation cap:elevated survival with reduced dimethyl sulfoxide concentration", 《CRYOBIOLOGY》, vol. 45, 31 December 2002 (2002-12-31) *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105324480A (zh) * 2013-06-28 2016-02-10 株式会社大塚制药工场 含有海藻糖及葡聚糖的哺乳动物细胞移植用溶液
CN103667440A (zh) * 2013-09-05 2014-03-26 谢小冬 Gata4基因snp位点的用途
CN104922155A (zh) * 2014-03-18 2015-09-23 中山大学孙逸仙纪念医院 治疗心脏疾病的细胞输送方法
US11673928B2 (en) 2015-03-03 2023-06-13 Regents Of The University Of Minnesota Genetically modified pig cells with an inactivated Etv2 gene
CN108472318A (zh) * 2015-06-30 2018-08-31 明尼苏达大学校董会 人源化心脏肌肉
US12089574B2 (en) 2015-06-30 2024-09-17 Regents Of The University Of Minnesota Humanized skeletal muscle
CN105079791A (zh) * 2015-09-18 2015-11-25 郑榆坤 一种刺激体内内源干细胞的组合物及其应用
CN106474456A (zh) * 2016-10-18 2017-03-08 广州赛莱拉干细胞科技股份有限公司 一种细胞制剂及其制备方法和应用
CN106619718A (zh) * 2016-10-18 2017-05-10 广州赛莱拉干细胞科技股份有限公司 一种细胞制剂及其制备方法和应用
CN108070645A (zh) * 2016-11-11 2018-05-25 中国科学院上海生命科学研究院 Stx-t在预防和/或治疗贫血或其相关疾病的应用
CN110945357A (zh) * 2017-07-18 2020-03-31 罗斯托克大学校行政管理中心1.1法律部 用于对心血管再生的响应的预测的方法
US11714093B2 (en) 2017-07-18 2023-08-01 Universität Rostock Method for prediction of response to cardiovascular regeneration based on detecting the amount of biomarkers
CN110945357B (zh) * 2017-07-18 2024-05-31 罗斯托克大学 用于对心血管再生的响应的预测的方法
CN107648592A (zh) * 2017-11-13 2018-02-02 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
WO2020030091A1 (zh) * 2018-08-10 2020-02-13 浙江楚沅生物科技有限公司 用于治疗组织坏死或改善心脏功能的药物
CN109266604A (zh) * 2018-10-10 2019-01-25 浙江神雁精准医疗科技有限公司 包含干细胞活性物质的组合物及其制备方法
CN109266604B (zh) * 2018-10-10 2020-11-10 浙江神雁精准医疗科技有限公司 包含干细胞活性物质的组合物及其制备方法
CN109769799A (zh) * 2019-03-20 2019-05-21 江苏瑞思坦生物科技有限公司 一种人脂肪组织保存液及其制备方法
WO2020228705A1 (zh) * 2019-05-16 2020-11-19 龚笑海 一种心脏治疗和保护的药物组合物

Also Published As

Publication number Publication date
KR101689415B1 (ko) 2016-12-23
WO2010133686A8 (en) 2012-03-08
JP6029468B2 (ja) 2016-11-24
IL216399A0 (en) 2012-01-31
SG175880A1 (en) 2011-12-29
CA2762584A1 (en) 2010-11-25
US20160279168A1 (en) 2016-09-29
HK1163500A1 (en) 2012-09-14
MX2011012183A (es) 2012-03-06
US9446076B2 (en) 2016-09-20
KR20120046107A (ko) 2012-05-09
WO2010133686A1 (en) 2010-11-25
RU2595801C2 (ru) 2016-08-27
TWI492707B (zh) 2015-07-21
ES2541212T3 (es) 2015-07-16
AU2010251151A1 (en) 2011-11-24
NZ623454A (en) 2015-12-24
BRPI1012116A2 (pt) 2016-03-15
CN107028980A (zh) 2017-08-11
NZ596162A (en) 2014-06-27
US20120128638A1 (en) 2012-05-24
US10086016B2 (en) 2018-10-02
JP2012527432A (ja) 2012-11-08
RU2011145370A (ru) 2013-06-27
TW201108935A (en) 2011-03-16
AU2010251151B2 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
CN102438636A (zh) 用于治疗心脏疾病的药物组合物
Badylak et al. Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds
Lee et al. Spherical bullet formation via E-cadherin promotes therapeutic potency of mesenchymal stem cells derived from human umbilical cord blood for myocardial infarction
JP2012527432A5 (enExample)
HK1248125A1 (zh) 缺血性组织的细胞疗法
Crisostomo et al. Dose-dependent improvement of cardiac function in a swine model of acute myocardial infarction after intracoronary administration of allogeneic heart-derived cells
MacDonald et al. Persistence of marrow stromal cells implanted into acutely infarcted myocardium: observations in a xenotransplant model
CN112262211B (zh) 一种诱导或改善间充质干细胞的创伤愈合性质的方法
Janssens Stem cells in the treatment of heart disease
US20030232431A1 (en) Cellular transplantation for heart regeneration
Seow et al. Mesenchymal stem cells as future treatment for cardiovascular regeneration and its challenges
Alrefai et al. Functional assessment of pluripotent and mesenchymal stem cell derived secretome in heart disease
EP2432482B1 (en) Pharmaceutical composition for the treatment of heart diseases.
Chiu Adult stem cell therapy for heart failure
CN106659560A (zh) 生殖腺来源的侧群干细胞
Codina et al. Current status of stem cell therapy in heart failure
US12460178B2 (en) Method of inducing or improving wound healing properties of mesenchymal stem cells
US20140219972A1 (en) Tissue engineering using progenitor cells to catalyze tissue formation by primary cells
HK1163500B (en) Pharmaceutical composition for the treatment of heart diseases
US20250242080A1 (en) Novel method to alter the proteome of a diseased heart by injection of ecm particles produced from decellularized 3d microtissues of human mesenchymal stem cells
Agashi The analysis of cell fate post-ejection through parenteral devices and the development of systems that aid the transportation of cell therapy products
HK1162051A (en) Ischemic tissue cell therapy
Zhang et al. A novel population of human bone marrow multipotent mesenchymal stem cells regenerates infarcted myocardium in rats
Subrahmanyam et al. Application of Stem Cells in Ischemic Heart Disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20120502

RJ01 Rejection of invention patent application after publication